Puma Biotech (PBYI) Licensing Partner CANbridge Pharmaceuticals Granted Marketing Approval in Mainland China for NERLYNX (neratinib)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. USO
5. GOOGL
6. APGE
7. MU
8. HOOD
9. DFTX
10. RGNX

Go back to Puma Biotech (PBYI) Licensing Partner CANbridge Pharmaceuticals Granted Marketing Approval in Mainland China for NERLYNX (neratinib)

Puma Biotech (PBYI) Tops Q1 EPS by 53c, Revenues Beat

May 7, 2020 6:00 PM EDT

Puma Biotech (NASDAQ: PBYI) reported Q1 EPS of ($0.20), $0.53 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $48.6 million versus the consensus estimate of $46.69 million.

We remain focused on providing a significant impact to cancer patients in need. The earlier-than-expected approval of the sNDA of NERLYNX in combination with capecitabine to treat adult patients with HER2-positive metastatic breast cancer who have... More